retromer-targeting gene therapy (MeiraGTx/Weill Cornell Medicine)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameretromer-targeting gene therapy (MeiraGTx/Weill Cornell Medicine)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionBeta amyloid A4 protein aggregation inhibitors
TargetsBeta amyloid A4 protein
Therapy Area/IndicationsAlzheimer DiseaseParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesWeill Medical College of Cornell University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMeiragtx LtdWeill Medical College of Cornell University
Active IndicationsN/A
Inactive IndicationsAlzheimer DiseaseParkinson Disease

Other Information

ATC CodeN/A
Related LinksN/A